Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese origin~* diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis~Exclusion Criteria:~* Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms~* HIV (human immunodeficiency virus) infections~* Hepatitis A~* Syphilis~* immunodeficiency~* rheumatic disease or Sjogren syndrome~* heart disease~* severe depression~* pregnancy or lactation~* conditions interfering with Magnetic Resonance Imaging (MRI)~* Gadolinium DTPA (Gadovist, contrast agent) allergy~* allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance~* participation in other trial

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1b (Betaseron, BAY86-5046) (Type: EXPERIMENTAL): Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)

Based on this trial design, predict the completion outcome and termination type (if applicable).